AbbVie Reports Third-Quarter 2024 Financial Results

Reports Third-Quarter Diluted EPS of $0.88 on a GAAP Basis, a Decrease of 12.0 Percent; Adjusted Diluted EPS of$3.00, an Increase of 1.7 Percent; These Results Include an Unfavorable Impact of 0.04 Per Share Related to Acquired IPR&D and Milestones Expense  Delivers Third-Quarter Net Revenues of 14.460 Billion, an Increase of 3.8 Percent on a Reported Basis or 4.9 Percent on an Operational Basis  Third-Quarter Global Net Revenues from the Immunology Portfolio Were $7.046 Billion, an Increase of 3.9 Per ...